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Abstract
Background: Postpartum haemorrhage (PPH) is a leading cause of preventable maternal mortality worldwide. The
World Health Organization (WHO) recommends uterotonic administration for every woman after birth to prevent
PPH. There are no standardised data collected in large-scale measurement platforms. The Every Newborn Birth
Indicators Research Tracking in Hospitals (EN-BIRTH) is an observational study to assess the validity of measurement
of maternal and newborn indicators, and this paper reports findings regarding measurement of coverage and
quality for uterotonics.
Methods: The EN-BIRTH study took place in five hospitals in Bangladesh, Nepal and Tanzania, from July 2017 to
July 2018. Clinical observers collected tablet-based, time-stamped data. We compared observation data for
uterotonics to routine hospital register-records and women’s report at exit-interview survey. We analysed the
coverage and quality gap for timing and dose of administration. The register design was evaluated against gap
analyses and qualitative interview data assessing the barriers and enablers to data recording and use.
Results: Observed uterotonic coverage was high in all five hospitals (> 99%, 95% CI 98.7–99.8%). Survey-report
underestimated coverage (79.5 to 91.7%). “Don’t know” replies varied (2.1 to 14.4%) and were higher after caesarean
(3.7 to 59.3%). Overall, there was low accuracy in survey data for details of uterotonic administration (type and
timing). Register-recorded coverage varied in four hospitals capturing uterotonics in a specific column (21.6, 64.5,
97.6, 99.4%). The average coverage measurement gap was 18.1% for register-recorded and 6.0% for survey-reported
coverage. Uterotonics were given to 15.9% of women within the “right time” (1 min) and 69.8% within 3 min.
Women’s report of knowing the purpose of uterotonics after birth ranged from 0.4 to 64.9% between hospitals.
Enabling register design and adequate staffing were reported to improve routine recording.
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Conclusions: Routine registers have potential to track uterotonic coverage – register data were highly accurate in
two EN-BIRTH hospitals, compared to consistently underestimated coverage by survey-report. Although uterotonic
coverage was high, there were gaps in observed quality for timing and dose. Standardisation of register design and
implementation could improve data quality and data flow from registers into health management information
reporting systems, and requires further assessment.
Keywords: Birth, Maternal, Coverage, Validity, Survey, Hospital records, Health management systems, Uterotonics,
Postpartum haemorrhage
Key findings
What is known and what is new about this study?
• Administration of prophylactic uterotonics immediately after birth is
an evidence-based intervention with the potential to reduce
postpartum haemorrhage (PPH) related deaths by half, yet there are
no reliable data tracking current coverage at national or global level
for most low and middle-income countries (LMICs).
• EN-BIRTH is the first and largest observational study (n = 23,015
women) with mixed methods to assess validity of uterotonic
measurement around the time of birth in three LMICs. Custom-built
tablet-based software generated time-stamped observation data.
Qualitative research explored barriers and enablers to inform
improvements for routine register recording of uterotonic use.
Survey-what did we find and what does it mean?
• Our findings show women’s reports about care received around the
time of birth underestimate uterotonics coverage; this aligns with
results from previous studies.
• There was low accuracy in survey data for details of uterotonic
administration (type of drug and timing of administration). We do
not recommend the addition of a uterotonic indicator to household
survey platforms.
• “Don’t know” responses were highest for women having a caesarean
birth.
Register-what did we find and what does it mean?
• Register design was critical: one did not capture uterotonics at all.
• When uterotonics were recorded in specific columns, coverage was
accurately measured in two hospitals but underestimated in two
hospitals, suggesting that good register design is necessary, but not
sufficient to achieve high quality data.
Gap analysis for quality of care and measurement
• Uterotonic coverage was high (> 99%) in these five hospitals.
• Actionable gaps were identified for timing—only 15.9% of women
received uterotonics within the recommended 1min, and 69.8% of
women within 3 min.
• The correct dose of oxytocin was received by 63.3% of women.
What next and research gaps?
• Uterotonic coverage was high, so we need to move beyond
coverage, and measure the quality of uterotonic administration.
Data sources such as local audits—as well as service readiness or
health facility assessments monitoring drug quality, stock
management and provider practices—are needed.
• Further research to explore data flow and quality at different levels
of the HMIS, and measures of effective coverage, is also warranted.
• Registers have potential to accurately capture provision of
uterotonics and could provide regular data with standardised design
and implementation.
Background
An estimated 295 000 maternal deaths occur annually
worldwide, 99% are in low and middle income countries
(LMICs) [1]. Approximately one-quarter of maternal
deaths are caused by haemorrhage, with postpartum
haemorrhage (PPH) estimated to affect around 7 million
women each year [2, 3]. Administration of prophylactic
uterotonics immediately after birth is an evidence-based
intervention with potential to halve PPH-related deaths
[4]. The World Health Organization (WHO) recom-
mends provision of prophylactic uterotonics for every
woman during the third stage of labour [5]. Five drugs
are available for PPH prevention: oxytocin, carbetocin,
ergometrine, misoprostol, and prostaglandin. An intra-
muscular (IM) injection of oxytocin plus ergometrine is
most effective, although oxytocin alone is currently the
most widely used uterotonic for facility births [4]. Des-
pite uterotonics being prioritised by WHO as an essen-
tial intervention, there are currently no national or
global level data to track coverage. Several estimates
based on expert opinion suggest low coverage [6, 7], and
one study found coverage under 50% in three settings
with low facility-birth rates [8].
Data on coverage, equity and quality of care are
fundamental to achieving Universal Health Coverage
and driving progress towards meeting the Sustainable
Development Goals for maternal and neonatal mortality,
as well as addressing morbidities, by 2030 [9, 10].
Quality of care at birth is prioritised by both Every
Newborn and Ending Preventable Maternal Mortality
(EPMM) strategies [11–13]. The Every Newborn Action
Plan, passed by all United Nations member states and
agreed by more than 80 development partners, includes
an ambitious measurement improvement roadmap with
an urgent focus on validating indicators for selected
maternal and newborn care interventions [13, 14].
Coverage is defined as the proportion of individuals
receiving an intervention (numerator: ‘number of women
receiving prophylactic uterotonics immediately after birth
in a health facility) from among the population in need
of that intervention (denominator: all women giving
birth in the facility’) [15, 16]. The use of live births as
the denominator is common for many maternal health
indicators such as place of birth, skilled attendance or
caesarean section [6], but should be carefully evaluated
for appropriateness against each indicator.
Population-based surveys such as the Demographic
and Health Survey (DHS) and Multiple Indicator Cluster
Survey (MICS) remain the major data sources for
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pregnancy outcomes and coverage of care data for the
75% of births occurring in LMICs [17–19]. Currently,
there is no uterotonic indicator measured in core survey
modules for DHS or MICS. Previous research to assess
validity of surveys suggest women do not accurately
report uterotonic administration [20–23]. In two of five
studies, agreed cut-offs for population-level validity were
met, but none met individual-level validity thresholds
[20, 21] (Additional file 1). This is compatible with fur-
ther evidence suggesting that asking women about clin-
ical interventions provided during or immediately after
birth is not reliable [20–24].
Facility-based births in LMICs have increased
dramatically in the last decade, now reaching four out of
every five births [25]. Data recorded in facility registers
and aggregated as part of health management
information systems (HMIS) offer an alternative
measurement platform, which could provide more
frequent information if concerns about data quality and
completeness are addressed [26]. Only one previous
observational study (n = 1867) in Nigeria has assessed
register-recorded accuracy compared with observer-
assessed coverage for uterotonics [27]. They found ac-
curate measurement with nearly complete agreement be-
tween register-recorded and observer-assessed data for
uterotonics, but were unable to analyse individual-level
validity due to high intervention prevalence [27]. In a de-
scriptive assessment of birth registers in 37 countries,
only 16 were tracking uterotonics use in any routine rec-
ord, including maternity registers, birth records, or elec-
tronic data platforms [7].
The Every Newborn – Birth Indicators Research
Tracking in Hospitals (EN-BIRTH) study was an
observational study of > 23,000 hospital births in three
countries (Tanzania, Bangladesh and Nepal). The
detailed protocol as well as overall validity results, are
reported elsewhere [15, 28].
Objectives
This paper is part of a supplement based on the EN-
BIRTH multi-country validation study, ‘Informing meas-
urement of coverage and quality of maternal and new-
born care’, and focuses on uterotonic provision with four
objectives:
1. Assess NUMERATOR accuracy/validity of
uterotonic coverage measurement using exit survey
of women’s report, and routine labour ward
registers compared to direct observation (gold
standard).
2. Compare DENOMINATOR options for
uterotonic coverage: including live births, or total
births (live births and stillbirths).
3. Analyse GAPS in coverage and quality of
care, and measurement for uterotonics:
coverage and quality gaps relating to provision of
care (right time, right drug, and right dose) and
experience of care (survey report of reason for
uterotonics given).
4. Evaluate BARRIERS AND ENABLERS to routine
labour ward register recording for uterotonics
through qualitative interviews regarding register
design filling and use.
Methods
EN-BIRTH study compared observation of uterotonic
administration for prevention of PPH (gold standard)
to coverage measured by women’s report at exit-
interview survey, and routine register records (Fig. 1).
Gold standard data were collected by trained clinical
researchers covering 24 h per day and using a
custom-built android tablet-based software applica-
tion [15].
Five comprehensive emergency obstetric care
(CEmOC) hospitals in three study countries were
included because they were implementing the selected
interventions: Maternal and Child Health Training
Institute, Azimpur and Kushtia General Hospital in
Bangladesh (BD), Pokhara Academy Health Sciences in
Nepal (NP), and Muhimbili National Hospital and
Temeke District Hospital in Tanzania (TZ). Participants
were consenting women admitted to the labour and
birth wards in the five study sites. Data collection was
undertaken between July 2017 and July 2018. This study
was granted ethical approval by institutional review
boards in all operating countries in addition to the
London School of Hygiene & Tropical Medicine
(Additional file 2). Results are reported in accordance
with STROBE statement checklists for cross-sectional
studies (Additional file 3).
Labour ward registers varied in design between the
five sites. Nepal had no uterotonics column. The original
Bangladesh hospital registers, and an additional
‘midwifery book’ maintained in Muhimbili, had a non-
specific column option (such as ‘drugs’). Bangladesh reg-
isters were updated to a standardised national register
during the study (Additional file 4). Tanzanian and the
updated Bangladesh registers used for this analysis had a
specific column for third stage management, labelled
‘AMTSL’ (active management of the third stage). In
Bangladesh, staff ticked the column if AMTSL (including
uterotonic administration) was considered done, and left
the column blank for not done. The AMTSL column in
Tanzania was completed with an “O, E or M” denoting
oxytocin, ergometrine or misoprostol administration.
There was a further column in the Tanzania registers
where staff could write “yes” if any type of uterotonic
Ruysen et al. BMC Pregnancy and Childbirth 2021, 21(Suppl 1):230 Page 3 of 17
was administered, or “no” if no uterotonic was adminis-
tered. Full details of register design and use are available
in Additional file 5.
One year of pre-study register data were extracted and
compared to one-year of during-after study register re-
cords to assess if the presence of external researchers in
the hospital affected register recording practice [28, 30].
To determine reliability of the observational data,
Cohen’s Kappa coefficients of agreement were calculated
for a 5% subset of cases where study supervisors simul-
taneously observed/extracted data for comparison with
data collector’s findings (Additional file 6) [28].
Objective 1: Numerator validation
We assessed the performance of a range of individual
and combined exit-survey questions around uterotonic
administration for prevention of PPH, compared to
observer-assessed practice (Fig. 2). All results were
stratified by mode of birth (vaginal births and caesar-
eans) and presented by individual site, and overall. For
indicators which had ≥10 counts in both columns of the
2 × 2 table, we calculated percent agreement, sensitivity,
and specificity, positive and negative predictive values,
area under the receiver operating curve, and inflation
factor. We combined hospital data using random effects
meta-analysis [28]. The percentage of women answering
“don’t know” to survey questions was calculated and
analysed in two ways: “don’t know” considered as “no”
and with “don’t know” excluded [28]. If there were miss-
ing data elements for the numerator or denominator,
the participant was excluded from the relevant sample.
Nepal was excluded from register-recorded validation
calculations given the absence of a uterotonic column.
Exit-interview indicator combinations were explored
using descriptive analysis comparing women’s report for
different combined indicator options with observation
data (Additional file 7). Quantitative analyses were
undertaken using StataCorp: Stata Statistical Software
(Release 16. In. College Station, TX; 2019).
Objective 2: Denominator comparison
The denominator was all women who gave birth;
however, we also calculated coverage using live birth
and total birth denominator options for observer-
assessed uterotonic coverage data. Descriptive analysis
was used to compare these results.
Fig. 1 Uterotonics: validation design, EN-BIRTH study. EN-BIRTH validation Design comparing observation gold standard with register-recorded
and women’s report on exit survey. EN-BIRTH data collection tools (observation checklist, register data extraction tool and exit-interview survey
tool) are published separately [15, 29]
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Objective 3: Gap analysis for coverage and quality of care
and measurement
We analysed four gaps for uterotonic administration: 1)
Coverage gap between the all-birth target population
and observed uterotonic coverage. 2) Quality of care gap
between any observed uterotonic coverage, and high
quality uterotonic coverage (within the right time < 1
or < 3 min, at the right dose 10 international units (IU)
oxytocin). 3) Measurement gap for register-records. 4)
Measurement gap for survey reports. Results were strati-
fied by site and by mode of birth, univariate logistic re-
gression was used to explore the association between
timing of uterotonic administration and mode of birth.
Objective 4: Barriers and enablers to data collection
Qualitative data collection tools for focus group interviews
were informed by the Performance of Routine
Information System Management (PRISM) conceptual
framework [31]. A purposive sample of hospital health
workers (nurses, midwives and doctors) and EN-BIRTH
data collectors was used. Interview audio recordings were
transcribed, translated and coded using a priori code and
included constructs for Technical, Organisational and Be-
havioural factors. NVivo 12 software was used to manage
data. Respondents also completed a checklist regarding:
who usually gives the uterotonic, documents care, which
documents uterotonics are recorded in, the order docu-
mentation occurs, and estimations of how long after birth
uterotonics are documented. More information is avail-
able within this supplement [32].
Results
Across five study hospitals, 23,724 (99.6%) women
consented to participate, with 23,015 (97.0%) observed
Fig. 2 Flow diagram for uterotonic cases, EN-BIRTH study (n = 23,015)
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and 20,632 (86.6%) completing an exit survey. Register
extraction was completed for 22,002 (92.7%) women
(Fig. 2). Participant characteristics are shown in Table 1.
Nearly half of participants were presenting with their
first pregnancy and participants from Tanzania were
most likely to be multiparous (2+ previous births). The
proportion of normal vaginal births varied between
hospitals, from 26.4% in Azimpur, BD to 91.6% in
Temeke, TZ (Table 1). The highest proportion of
caesarean births were in Azimpur BD (72.8%) and
Muhimbili, TZ (55.8%). 688 (3.2%) women experienced
PPH during the study.
Objective 1: Numerator validation
Observed uterotonic coverage was consistently high
across all sites and modes of birth (range from 98.4% in
Muhimbili, TZ to 99.9% in Pokhara, NP) (Fig. 3). Of
those administered uterotonics, > 99% received oxytocin,
irrespective of mode of birth (Additional file 8).
Exit-interview survey-reported findings
Survey-reported uterotonic coverage ranged from 79.5%
in Muhimbili to 91.7% in Temeke TZ; 84.7% (95% CI
79.1–89.5) overall (Additional file 9). Women who had a
vaginal birth were more likely to accurately report
Table 1 Characteristics of women observed in labour and delivery wards, EN-BIRTH study (n = 23,015)
Hospitals Total
Bangladesh Nepal Tanzania
Azimpur Tertiary Kushtia District Pokhara Regional Temeke Regional Muhimbili National
n (%) n (%) n (%) n (%) n (%)
Total 2910 2412 7370 6748 3575 23,015
Woman’s Age
< 18 years 25 (0.9) 3 (0.1) 311 (4.2) 26 (0.4) 8 (0.2) 373 (1.6)
18–19 years 475 (16.3) 197 (8.2) 817 (11.1) 767 (11.4) 159 (4.4) 2415 (10.5)
20–24 years 1158 (39.8) 954 (39.6) 3080 (41.8) 2314 (34.3) 722 (20.2) 8228 (35.8)
25–29 years 867 (29.8) 736 (30.5) 2114 (28.7) 1697 (25.1) 1134 (31.7) 6548 (28.5)
30–34 years 297 (10.2) 373 (15.5) 827 (11.2) 1146 (17) 924 (25.8) 3567 (15.5)
35+ years 88 (3) 149 (6.2) 221 (3) 798 (11.8) 628 (17.6) 1884 (8.2)
Woman’s education
No education 39 (1.3) 77 (3.2) 268 (3.6) 202 (3) 66 (1.8) 652 (2.8)
Primary incomplete 111 (3.8) 127 (5.3) 252 (3.4) 81 (1.2) 45 (1.3) 616 (2.7)
Primary complete 339 (11.6) 347 (14.4) 302 (4.1) 31 (0.5) 5 (0.1) 1024 (4.4)
Secondary incomplete 985 (33.8) 954 (39.6) 1637 (22.2) 4053 (60.1) 1299 (36.3) 8928 (38.8)
Secondary complete or higher 1273 (43.7) 870 (36.1) 4509 (61.2) 2346 (34.8) 2146 (60) 11,144 (48.4)
Don’t know 163 (5.6) 37 (1.5) 402 (5.5) 35 (0.5) 14 (0.4) 651 (2.8)
Parity
Nullipara 1350 (46.4) 1038 (43) 4402 (59.7) 2917 (43.2) 1363 (38.1) 11,070 (48.1)
Multipara 1504 (51.7) 1369 (56.8) 2961 (40.2) 3816 (56.6) 2207 (61.8) 11,857 (51.5)
Missing 56 (1.9) 5 (0.2) 7 (0.1) 15 (0.2) 5 (0.2) 88 (0.4)
Mode of birth
Normal vaginal birth 767 (26.4) 1364 (56.6) 5840 (79.2) 6184 (91.6) 1506 (42.1) 15,661 (68)
Vaginal births: Breech,
Vacuum/Forceps
1 (0) 0 (0) 349 (4.8) 10 (0.1) 9 (0.2) 369 (1.6)
Caesarean Section 2119 (72.8) 972 (40.3) 1140 (15.5) 472 (7.0) 1995 (55.8) 6698 (29.1)
Estimated Blood Loss at birth
Normal: ≤500mls 2792 (97.2) 2236 (95.9) 6993 (95.6) 6289 (96.2) 3026 (90.1) 21,336 (95.2)
PPH: > 500 - ≤1000 mls 48 (1.7) 63 (2.7) 133 (1.8) 157 (2.4) 243 (7.2) 644 (2.9)
Severe PPH > 1000 mls 6 (0.2) 11 (0.5) 3 (0.04) 12 (0.2) 12 (0.4) 44 (0.2)
Missing 26 (0.9) 22 (0.9) 185 (2.5) 80 (1.2) 79 (2.4) 392 (1.8)
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receiving uterotonics compared with women who gave
birth by caesarean (Fig. 3). Survey-reported coverage for
vaginal births was 89.3% (96% CI 85.3–92.8) overall and
ranged from 80.8% in Azimpur BD to 94.1% in Temeke
TZ. For caesarean births survey-reported coverage was
66.3% (95% CI 44.0–85.3) and ranged from 50.2% in
Temeke TZ to 92% in Kushtia BD (Additional file 9).
The largest differential between survey-reported utero-
tonic coverage was in Pokhara NP where observer-
assessed coverage was 99.9% (95% CI 99.8–100%)
Fig. 3 Coverage rates for uterotonic administration measured by observation, register and exit-survey (95% CI), EN-BIRTH study (n = 23,015). n =
23,015 observer assessed births; 20,632 women with survey-reported births & 14,221 with register records, (noting that for validity analysis, n = all
register data from Tanzania + revised register data from Bangladesh) [28]. BD = Bangladesh, NP = Nepal, TZ = Tanzania. Pokhara, Nepal has no
register column for recording uterotonics (n = 6838). *Pooled using random effects
Fig. 4 ‘Don’t Know’ replies for exit-survey reported uterotonic provision, EN-BIRTH study (n = 20,632) *individually weighted mean. Cut-off ranges
adapted from WHO Data Quality Review, Module 2 "Desk review of data quality” [33]
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compared with 91.1% (95% CI 90.4–91.8) survey-reported
for vaginal births, and 29.6% (95% CI 26.8–32.5) survey-
reported for caesarean births (Additional file 9).
Women who had a caesarean section were more likely to
report “don’t know” for any uterotonic indicator than those
with vaginal birth. “Don’t know” replies were highest
(> 20%) for women with caesarean births reporting on
medication administration immediately after birth (Fig. 4).
Descriptive analysis comparing reported coverage of
potential combined uterotonic indicator options with
observed coverage, showed no difference between the
various combinations (Additional file 7).
Register-recorded findings
For hospitals with a specific column, register-recorded utero-
tonic coverage was 77.9% (95% CI 37.8–99.5) and ranged
from 21.6% (Kushtia, BD) to 99.4% (Azimpur, BD). Register-
recorded coverage was lowest in Pokhara NP where this data
element is not captured (Fig. 5 and Additional file 10).
When capturing uterotonics, register-recorded coverage
estimates were higher for vaginal births (86.6, 95% CI
55.0–100.0) than caesareans (68.5, 95% CI 15.5–100.0).
Percent agreement between register-recorded and
observer-assessed coverage was higher with not recorded
results excluded: 86.1% (95% CI 48.5–100.0) for all
modes of birth combined, compared to 77.2% (95% CI
37.7–99.3) when not-recorded results were included as
‘not given’ (Additional file 10). Positive predictive value
was > 99% for all modes of birth (Additional file 10).
Descriptive analysis of the Bangladesh specific results
found that register-recorded coverage of uterotonic
administration increased with the introduction of revised
registers that included a specific column for third stage
labour management. In Azimpur there was an 81.6% in-
crease in the number of register-recorded cases, and
21.6% increase in Kushtia (Additional file 11).
Objective 2: Denominator comparison
Uterotonic coverage was over-estimated using the live
birth denominator in all EN-BIRTH hospitals, the abso-
lute difference ranged between − 1.3 and − 6.8%, and
relative difference ranged from − 0.1 to 0 (Table 2).
Objective 3: Gaps analysis for coverage and quality of
care, and measurement
The coverage gap for oxytocin for PPH prevention
within 30min of birth was small (1.9%) in all sites
(Fig. 6). Quality gap analysis showed timing distribution
was different between each hospital and by mode of
birth (Additional file 12). Oxytocin was administered
more quickly for caesarean births than vaginal births,
and overall most women (88.8% Azimpur, 90.3%
Kushtia, 68.6% Pokhara, 52.4% Temeke and 76.7%
Muhimbili) received oxytocin within 3 min (the “right
time”, Fig. 7). The distribution of Oxytocin dose, “right
content”, showed that 66.3% of women received 10 IU of
Oxytocin, 21.8% 20 IU, and 4.25% 40 IU
(Additional file 13). Of those who received 40 IU, 2.2%
were observed to have a blood loss of > 500mls
(Additional file 14). Women giving birth via caesarean
section were more likely to receive higher doses of
Oxytocin than those with vaginal births. In observed
Fig. 5 Hospital register design and completion for uterotonics by site, EN-BIRTH study (n = 14,211). Register Recorded n = 14,221 (for validity
analysis n = all register data from Tanzania + revised register data from Bangladesh) [28]. ~ Revised Register design, further details available in
Additional file 4. *Completeness calculations are “not possible” for Bangladesh registers as the instructions state leave blank if intervention/
practice is not done. Cut-off ranges adapted from WHO Data Quality Review, Module 2 “Desk review of data quality” [33]
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cases, the route of administration was intramuscular
(IM) for 65.2%, and intravenous (IV) in 34.3% of births
(Additional file 8).
The measurement gap was 18.1% for register-recorded
and 6% for survey-reported coverage. For women who
had a vaginal birth, 39% (ranging from 0.7% in Azimpur
to 67.6% at Temeke) could report the purpose of the
uterotonic medication (‘to prevent haemorrhage’). For
caesarean births, this dropped to 6.9% (ranging from
0.3% in Azimpur to 17.1% in Temeke) (Additional file
8). Less than 2.5% of women could name the drug they
were given (Additional file 8).
Objective 4: Barriers and enablers to data collection
We identified three categories under which to group
emerging themes regarding barriers and enablers to
routine recording of uterotonic administration in
hospital registers: 1) Register or system design; 2)
Register filling or completion; 3) Register use (Fig. 8)
[32].
Register or system design
Within this category, two themes emerged for
uterotonic recording. Focus group participants talked
about the complexity of health data systems and the
specific register design for uterotonics. Across all
sites, health workers identified multiple places where
they were expected to document information about
care during the third stage of labour, including the
register, clinical records, partograph, and drug chart.
Many staff reported they did not know who would
be taking primary responsibility for documentation
(Additional files 15 and 16).
These challenges were underlined in Kushtia BD and
Muhimbili TZ, where register performance was lower:
‘She will go to the nursing station to do her docu-
mentation in the health management system tool,
then fills the midwifery book, the books are in differ-
ent places and are far from the patient and the de-
livery room.’
–Health worker, Muhimbili TZ
Participants reported that design of the register,
amount of space and inclusion of a specific column for
the uterotonic documentation is needed to facilitate high
quality data collection:
‘There is no such space to record, maybe we have ad-
ministered a certain amount of oxytocin or
ergometrine, no space for that.’
–Data collector, Muhimbili TZ
Register filling or completion
Lack of health workers (quantity and capacity) was
identified as a critical challenge throughout all the focus
group discussions and was a key barrier to uterotonic
data collection among other indicators:
‘We have a shortage of manpower and time … We
need time to examine and provide the treatment
thoroughly.... But also we have to maintain the docu-
mentation.’
–Health worker, Azimpur BD
Evidence from Temeke TZ suggests that some of these
challenges can be addressed with good organisation of
workspaces to ensure that clinical environments are
enabling with the required register books, computers,
and stationary positioned in convenient clinical locations
Table 2 Denominator comparisons for uterotonic indicator, EN-BIRTH study (n = 23,015)
Bangladesh Nepal Tanzania
Azimpur Tertiary Kushtia District Pokhara Regional Temeke Regional Muhimbili National
Number of women who gave birth 2910 2412 7370 6748 3575
Uterotonic observed given 2858 2333 7221 6653 3485
Total births 2936 2459 7442 6869 3765
Live births 2896 2308 7175 6634 3509
Uterotonic coverage among women who
gave birth (%)
98.9 99.8 99.9 99.3 98.4
Uterotonic coverage using live birth
denominator (%)
98.7 101.1 100.6 100.3 99.3
Uterotonic coverage using all birth
denominator (%)
97.3 94.9 97.0 96.9 92.6
Relative difference % 0.0 −0.1 0.0 0.0 −0.1
Absolute difference % −1.3 −6.2 −3.6 −3.4 −6.8
Legend: N = 23,051 women observed to give birth
Uterotonic coverage is calculated using number of women who gave birth (rather than “all” or “live” births)
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Fig. 6 Gap analysis for uterotonic coverage and quality, EN-BIRTH study. N = 23,015 observer assessed births: 20,632 survey reported births and
14,221 register recorded (all cases in Tanzania and those from revised register data from Bangladesh) BD= Bangladesh, NP =Nepal, TZ = Tanzania
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that facilitate health workers to remain near service
users:
‘There is a specific place kept and arranged
for documenting all the provided care … they
are supposed to be there, equipment like
books for recording and pens [are there],
and it is not far’
–Data collector, Temeke TZ
Healthcare staff reported that they are usually
completing care during the third stage of labour and
documentation simultaneously. Staff from Kushtia and
Muhimbili identified the location of registers as
problematic, which was also identified as a register-
recording barrier, across all sites, for women giving birth
in the operating theatres Fig. 8.
Participants from Kushtia BD and Muhimbili TZ
reported supply challenges with basic equipment
Fig. 7 Timing of oxytocin administration, EN-BIRTH study (n = 22,121). N = 22,121 (women observer-assessed to receive oxytocin from 0 to 30min
after birth). BD = Bangladesh, NP = Nepal, TZ = Tanzania
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including multiple register stock-outs in Kushtia, and the
requirement for staff to supply their own pens:
‘We usually buy our pen ourselves, we do not get a
pen from the office.’
-Health worker, Kushtia BD
Register use
Respondents from Temeke TZ and Azimpur BD
reported these sites have instituted regular opportunities
for staff to use and reflect on their data. Moreover, staff
in these hospitals were using data for a variety of
purposes in their own practice:
‘These documents show what the patient is suffering
from and what medication is given … Also these doc-
uments are important for research works, planning,
improving health services, helping secure you in the
court, and in statistics. The documents are very im-
portant in improving health services.’
–Data collector, Temeke TZ
Feedback was consistently valued by staff in all
hospitals, and health workers suggested leadership was
an enabling factor for documentation. Temeke TZ had
highly accurate register reporting for uterotonics. Staff
reported being well-supported by management with
regular feedback, training and opportunities to use their
data during budget planning, stock management, audit
and monitoring:
‘Leadership in general from the lower level to the
upper level should have good communication and
cooperation to ensure that everything is well
documented and records are kept with good quality.’
–Data collector, Temeke TZ
Staff from EN-BIRTH sites with more accurate
register-recording of uterotonic coverage reported train-
ing as an essential component. Managerial gaps and lack
of training were cited as barriers to documentation in
Kushtia, the site with lowest performing register-
recording.
‘However we are not well trained’.
–Health worker, Kushtia BD
Discussion
Postpartum haemorrhage remains a leading cause of
preventable maternal mortality. Despite WHO
recommendations for universal access to prophylactic
uterotonics, there are no nationally representative data
to track coverage and quality of this intervention [6, 7].
EN-BIRTH is the largest measurement validation study
Fig. 8 Barriers and enablers to routine register recording of uterotonic administration, EN-BIRTH study. This Figure illustrates the overall barriers
and enablers to facility based data collection identified by EN-BIRTH participants [32]. The bold text are the issues specific to uterotonics
administration. The transition from red to green is a reminder that most factors identified by participants could serve as either a barrier or
enabling factor depending on the facility-level resources and management
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to date, with more than 10 times the number of partici-
pants of previous studies, and assessed both survey-
reported and register-recorded indicators.
Survey-reported data for assessing uterotonic coverage
was problematic, with high “don’t know” replies for
caesarean births, and lower accuracy than the better
performing registers. Our findings align with previous
validation studies suggesting low individual-level accur-
acy for survey measures of uterotonic coverage [20–24].
There was also poor consistency between observer-
assessed and survey-reported events around timing, and
type of uterotonic administration. Our survey data was
collected at exit-interview on discharge from the hos-
pital; and we anticipate that the discrepancy between
woman’s report and gold standard data may increase
over time in line with other study findings [20–24].
Our results underline that accurate report in surveys is
challenging for events around the time of birth, especially
for women receiving more complex clinical care (e.g. PPH
management or caesarean section). This is unlikely to be
recall alone; the women’s knowledge will depend on the
quality of information provided by healthcare staff, and if
informed consent was elicited [20, 24]. Indicators
regarding knowledge of care and rationale could serve as
tracers for respectful care, as women have a right to
informed decision making and autonomy [34, 35]. These
rights are increasingly recognised: respectful and dignified
care was the number one demand from the recent ‘what
women want’ campaign with > 1 million participants
across 114 countries [36]. Participants experiencing
caesareans were less likely to report that the health worker
explained the purpose of uterotonic medication
(Additional file 8). Given caesarean section rates are
increasing globally [37], further research is needed on how
accuracy of women’s report is effected by both direct
(anaesthetics or sedatives) and indirect processes. This
includes what information is given to women about
treatment of them and their baby, and issues around
gaining her informed consent.
Register completion varies [7, 20, 27, 38–41]. The two
highest performing hospitals achieved high sensitivity
(97.6–99.5%) and percent agreement (97.3–99.0%)
between register-recorded and observer-assessed cover-
age. Pokhara NP had no column or space available in
the register for uterotonic documentation. These find-
ings draw attention to the requirement for clear register
design around priority measures and the need for more
global guidance and standardisation, especially given
there are multiple stakeholders and only limited space
and capacity for the inclusion of data elements in rou-
tine registers. Wider use of national electronic HMIS
tools, such as District Health Information Software 2
(DHIS2) [42, 43], provide important platforms for faster
uptake. Evidence from Nigeria suggests that tracking of
maternal and newborn indicators through HMIS is pos-
sible with strong multi-partner collaboration at all levels
of the health system to rationalise data flow, and provide
supervision with data quality review, feedback and data
reporting [27].
Register design is necessary but not sufficient to achieve
high quality data, inclusive training and implementation
strategies are also imperative. Despite sharing the same
register design and layout, results differed between
Temeke and Muhimbili TZ, and between Azimpur and
Kushtia BD after implementation of the new national
register. Our results support evidence that data collection
and management processes represent a heavy workload
for health workers [39, 44–46], who face competing
priorities and challenges on their time. Managerial
support for data collection including supervision, feedback
and review are therefore essential [27].
Maternal mortality remains high in many settings
despite good coverage of facility births [47]; this
divergence in expectation is usually attributed to quality
gaps in service provision. Yet to be sure, we need more
granular data on the content and quality of care. There
was a quality gap for timing with less than 20% of
women receiving oxytocin within 1 minute of birth as
recommended by WHO [5], although the majority were
within ≤3 min (Fig. 7). We recommend further research
around the precise timing need for uterotonic
administration [48], especially as early indications from
an ongoing trial assessing tranexamic acid to treat PPH,
suggest that the positive effect of administration reduces
with every minute of delay [49].
Uterotonic coverage was high in our study sites,
although these high caseload referral centres are not
representative of all facilities in LMICs. Several studies
indicate that quality of care is lower in primary-level facil-
ities, especially those with a low case-load [47]. We used
the elements of timing, and dose of drug use as quality
measures. However, Oxytocin is light and heat sensitive
and should be stored between 2 and 8 °C for extended
shelf life [5]. Stock-outs, poor adherence to manufacturer
guidelines and prolonged exposure to high temperatures
reduce the availability of effective Oxytocin at the point of
care [50]. Oxytocin samples tested from multiple LMICs
were found to have insufficient active ingredient, with up
to 74% of tested samples failing [51, 52]. Given this would
likely fall outside routine measurement systems, further
work to examine these aspects of quality are needed.
Denominators are crucial for public health decision-
making [53]. Worldwide, four in every five births are es-
timated to be taking place in facilities and almost 81%
are supported by a skilled birth attendant, but the poor-
est women in the poorest countries are still without ac-
cess [1, 25]. Whilst most of the numerator of women
given injectable uterotonics may be captured in a facility
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(given this is WHO policy), a denominator of only facil-
ity births omits home births [16]. Some countries do
have a policy supporting misoprostol use for non-facility
births, but these data are not currently being measured.
Many LMICs estimate denominators via census-derived
population estimates (i.e. for immunisation) [54]. This is
also feasible using an estimated total birth denominator
for a given population, such as a district. If there are
many births in the private sector, HMIS should aim to
include the count data of women given uterotonics and
the relevant denominator. In India, the private and non-
profit sectors are now mandated to report selected data
to the government HMIS [54, 55].
Strengths and limitations
EN-BIRTH study strengths include use of direct
observation as gold standard, the large number of
participants, time-stamped data, stratification of results
by mode of birth, and five differing hospitals from three
LMICs. Unfortunately, even the high number of ob-
served births were not able to mitigate statistical chal-
lenges validating indicators with high prevalence,
especially those only calculated for observations with
≥10 counts in each column of the 2 × 2 tables to assess
sensitivity, specificity, inflation factor and area under the
curve [56]. The gold standard could also be susceptible
to errors in data recording and interpretation, especially
for estimated blood loss. Some of these risks were re-
duced via use of the custom-built tablet-based applica-
tion, standardised training, and supervision throughout
data collection. We also assessed inter-observer error by
double entering observations for 5% of cases, and found
good agreement for uterotonics (Additional file 6). Study
data were collected in CEmOC level hospitals where
higher case-loads, access to multidisciplinary teams, and
potentially higher levels of supervision and training
might mean that both the provision and recording of
uterotonic drugs are completed to a higher standard.
The Hawthorne effect (whereby a study changes prac-
tice) could have resulted in improved register documen-
tation and/or uterotonic provision by health workers.
However, comparison of registers pre-study with during-
after register records shows no significant change in
completeness or documentation practises [28].
Research gaps for improving measurement
Systematic research and investment in implementation
are needed to improve register design and use. Where
coverage is high, a simple uterotonics coverage indicator
might be insufficient to drive quality improvement.
Other measures may be required such as health facility
assessments regarding drug quality, and stock
management, or use of specific audits. There is potential
for linking databases (such as survey and facility-based
data) but this may require special studies and complex
analyses [6, 57–60].
Assessment of data flow within HMIS and inter-
operability with related platforms, such as supply logis-
tics systems, are also needed. This could be undertaken
as part of a feasibility assessment of maternal and new-
born HMIS tool kits in a range of LMICs and humani-
tarian settings. It should include data quality
assessments at different levels of the HMIS, including
costs for data collection and assessment of usefulness to
policymakers.
Conclusions
EN-BIRTH findings for uterotonics measurement are
compatible with existing evidence suggesting that asking
women about clinical interventions during or
immediately after birth is unreliable [20–24], especially
following caesarean section. Based on this evidence, we
do not recommend the addition of a uterotonic
indicator to household survey platforms such as DHS
and MICS. Registers have potential to accurately capture
coverage of uterotonics and could provide timely data;
however, this requires work on register design,
standardisation and improved global guidance. A well-
designed, parsimonious, standardised register is neces-
sary but not sufficient to collecting consistent high-
quality data. Importantly, those who enter the data are
often over-worked health professionals who need to
know why these data matter for their own use, and for
the women they care for. Feedback mechanisms and
data use are important enablers to drive improvements
in register-recording practices.
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